Gait Assessment in Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Table 1

Study protocol, including the intervention performed, follow-up frequency, and definition of clinical status.

Target patients	Newly diagnosed CIDP patients starting treatment or relapsed CIDP patients warranting new treatment (CDAS 5)
Treatment applied	Induction treatment regimen; (i) IVIg days every 3 weeks; OR; (ii) PDN (60 mg for 6 weeks with subsequent) or DXM days every 4 weeks
Clinical control	Every 2 months
Scales	INCAT, IRODs, MRC-SS, grip strength, TUG, 10MWT, 30SCS
Clinical status	Improvement; (1) Improvement reported by the patient; (2) Improvement equal to or greater than MCID in ≥1 CIDP scales (I-RODS, INCAT, MRC-SS, grip strength)

IVIg: intravenous immunoglobulins; PDN: prednisone; DXM: dexamethasone; INCAT: Inflammatory Neuropathy Cause and Treatment; I-RODS: Inflammatory Rasch-Built Overall Disability Scale; MRC-SS: manual muscle strength according to the Medical Research Council sum score; TUG: Timed Up and Go; 10MWT: 10-Meter Walk Test; 30SCS: 30-Second Chair Stand; MCID: minimum clinically important difference.